Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd (SHE:301126)
China · Delayed Price · Currency is CNY 10.30
+0.06 (0.59%)
At close: Aug 27, 2026
SHE:301126 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
| 2,116 | 2,524 | 2,144 | 2,691 | 3,075 | 4,686 | |
Market Cap Growth | -18.32% | 17.72% | -20.30% | -12.49% | -34.38% | - |
Enterprise Value | 5,360 | 5,753 | 5,169 | 4,693 | 3,968 | 5,441 |
Last Close Price | 10.30 | 12.29 | 10.34 | 12.86 | 14.66 | 22.30 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 80.69 | 78.45 | 60.20 | 68.65 |
PS Ratio | 0.40 | 0.49 | 0.41 | 0.69 | 0.93 | 1.81 |
PB Ratio | 1.32 | 1.59 | 1.16 | 1.51 | 1.69 | 2.79 |
P/TBV Ratio | 7.18 | 8.80 | 4.26 | 3.02 | 2.13 | 2.83 |
P/OCF Ratio | - | - | 89.20 | 99.18 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.03 | 1.12 | 0.99 | 1.20 | 1.21 | 2.10 |
EV/EBITDA Ratio | 30.57 | 39.87 | 20.88 | 22.77 | 30.32 | 38.21 |
EV/EBIT Ratio | 66.12 | 69.20 | 26.27 | 38.27 | 36.66 | 42.41 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 2.29 | 2.31 | 1.78 | 1.45 | 0.89 | 0.45 |
Debt / EBITDA Ratio | 20.90 | 15.39 | 9.57 | 12.49 | 10.70 | 4.99 |
Net Debt / Equity Ratio | 1.96 | 1.93 | 1.44 | 1.08 | 0.53 | 0.00 |
Net Debt / EBITDA Ratio | - | 21.31 | 10.77 | 9.34 | 7.39 | 0.04 |
Net Debt / FCF Ratio | -28.72 | -12.12 | -16.35 | -9.64 | -1.38 | -0.03 |
Asset Turnover | 0.82 | 0.82 | 0.91 | 0.85 | 0.95 | 1.00 |
Inventory Turnover | 4.87 | 4.70 | 5.64 | 6.28 | 8.49 | 8.54 |
Quick Ratio | 0.73 | 0.70 | 0.77 | 0.96 | 1.27 | 1.98 |
Current Ratio | 1.01 | 0.99 | 1.12 | 1.30 | 1.66 | 2.27 |
Return on Equity (ROE) | -13.24% | -13.29% | 2.83% | 2.11% | 3.16% | 5.02% |
Return on Assets (ROA) | 0.79% | 0.83% | 2.15% | 1.66% | 1.95% | 3.10% |
Return on Invested Capital (ROIC) | 1.72% | 1.81% | 3.23% | 2.96% | 3.52% | 5.73% |
Return on Capital Employed (ROCE) | 3.40% | 3.60% | 6.80% | 4.50% | 5.10% | 7.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Earnings Yield | -11.33% | -9.61% | 1.24% | 1.27% | 1.66% | 1.46% |
FCF Yield | -5.16% | -10.05% | -7.61% | -7.42% | -22.85% | -4.16% |
Dividend Yield | 1.04% | 0.18% | 0.79% | 0.31% | 0.20% | 0.15% |
Payout Ratio | - | - | 347.51% | 211.22% | 80.71% | 45.37% |
Buyback Yield / Dilution | -13.78% | -0.51% | -1.32% | 1.25% | -31.70% | -0.47% |
Total Shareholder Return | -12.74% | -0.34% | -0.53% | 1.56% | -31.50% | -0.31% |